A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
Prelude Therapeutics
Prelude Therapeutics
Incyte Corporation
Grupo Español de Enfermedades Mieloproliferativas Crónicas PH Negativas
Washington University School of Medicine
Stanford University
City of Hope Medical Center
Fondazione Policlinico Universitario Agostino Gemelli IRCCS